Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
äŒæ¥ã³ãŒãDARE
äŒç€ŸåDare Bioscience Inc
äžå Žæ¥Apr 10, 2014
æé«çµå¶è²¬ä»»è
ãCEOãJohnson (Sabrina Martucci)
åŸæ¥å¡æ°21
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Apr 10
æ¬ç€Ÿæåšå°3655 Nobel Dr Ste 260
éœåžSAN DIEGO
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·92122-1050
é»è©±çªå·18589267655
ãŠã§ããµã€ãhttps://www.darebioscience.com/
äŒæ¥ã³ãŒãDARE
äžå Žæ¥Apr 10, 2014
æé«çµå¶è²¬ä»»è
ãCEOãJohnson (Sabrina Martucci)